Previous research reported that S100A6 impaired lymphatic endothelial cells tight junction and increased the transendothelial migration of neutrophils in breast cancer,[32] indicating that S100α6 might be a potential mLECs damage biomarker after SAH. Here, S100A6 is linked to breast cancer.